A recent article in Molecular Cancer Therapeutics shows the anticancer potential of an inhibitor of ubiquitin-specific protease 7 (USP7).
28 August, 2009
Genentech, Inc. announced recently that a Phase III study of Avastin® (bevacizumab) in combination with chemotherapy increased the time that women with metastatic HER2-negative breast cancer whose initial chemotherapy had stopped working lived without the disease worsening (progression-free survival), compared with chemotherapy alone.
27 August, 2009
Cleveland BioLabs, Inc. announced recently that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its U.S. Patent Application Number 11/421,918, titled ‘Modulating Apoptosis’. Allowed claims cover the method of protecting a mammal from radiation using flagellin or its derivatives, including Protectan CBLB502.
26 August, 2009
Healthcare workers and parents might refuse to get immunized or vaccinate their children against a pandemic virus if they believe the risks of a novel vaccine outweigh the benefits, according to research published in Emerging Health Threats Journal.
25 August, 2009
Medical diagnosis requires doctors to make difficult decisions, beginning with the selection of the right diagnostic method.
24 August, 2009
For the first time, scientists have used a genetically engineered ‘friendly’ bacterium to deliver a therapy.
21 August, 2009
A new experimental treatment for multiple sclerosis completely reverses the devastating autoimmune disorder in mice and might work exactly the same way in humans, say researchers at the Jewish General Hospital Lady Davis Institute for Medical Research and McGill University in Montreal.
20 August, 2009
Forty years ago men landed on, and walked on, the moon.
20 August, 2009
79% of treatment-naïve HIV-1 infected adults taking once-daily PREZISTA (darunavir) reached an undetectable viral load (the goal of HIV treatment) at week 96, compared to 71% of adults taking lopinavir, the current standard.
19 August, 2009
Deal combines ChemNavigator's database of searchable chemical compounds and cheminformatics tools with Sigma-Aldrich chemical services.
18 August, 2009
The Royal Society of Chemistry will be re-launching ChemSpider, its free online resource for chemical structure searching, at the American Chemical Society’s Fall 2009 National Meeting and Exposition in Washington, DC, August 16–22.
17 August, 2009
New technology designed to analyze large numbers of novel marine microbes could lead to more efficient and greener ways to manufacture new drugs for conditions such as epilepsy, diabetes, and flu and other viruses, as well as improving the manufacture of other products, such as agrochemicals.
14 August, 2009
Medicago, the John Innes Centre and Plant Bioscience Limited announced recently that Medicago's 14-day production of the H1 virus-like particle antigen was achieved using, among other technologies, a technology that was invented by John Innes Centre researchers and is licensed by Plant Bioscience Limited to Medicago.
13 August, 2009
The international Biological and Environmental Reference Materials 12 symposium, which was organized by LGC in conjunction with the BERM committee, was opened by Lord Drayson, UK Minister for Science and Innovation.
12 August, 2009
Biota Holdings Limited has announced successful results from the Asian Phase III clinical trials of CS-8958, its second-generation influenza treatment. CS-8958 has now been assigned the new name of ‘laninamivir’ by the World Health Organization under its International Non-proprietary Names drug identification system.
10 August, 2009
A compound initially isolated from a soft coral (Capnella imbricata), collected at Green Island off Taiwan, could lead scientists to develop a new set of treatments for neuropathic pain.
05 August, 2009
The European Commission has approved the Marketing Authorisation Application for Otsuka's oral once-daily medication Samsca™ (tolvaptan), a selective V2-vasopressin receptor antagonist, for the treatment of hyponatraemia secondary to SIADH in adults.
04 August, 2009
Shire has recently reported positive results from the first of three Phase III studies of velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease.
03 August, 2009